- Home
- PRCT vs HCM Comparison
PRCT vs HCM Comparison
Compare PRCT & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRCT
- HCM
- Stock Information
- Founded
- PRCT 2009
- HCM 2000
- Country
- PRCT United States
- HCM Hong Kong
- Employees
- PRCT N/A
- HCM N/A
- Industry
- PRCT Medical Specialities
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- PRCT Health Care
- HCM Health Care
- Exchange
- PRCT Nasdaq
- HCM Nasdaq
- Market Cap
- PRCT 3.2B
- HCM 2.5B
- IPO Year
- PRCT 2021
- HCM N/A
- Fundamental
- Price
- PRCT $58.00
- HCM $13.89
- Analyst Decision
- PRCT Strong Buy
- HCM Hold
- Analyst Count
- PRCT 7
- HCM 1
- Target Price
- PRCT $90.00
- HCM $19.00
- AVG Volume (30 Days)
- PRCT 850.8K
- HCM 62.8K
- Earning Date
- PRCT 04-24-2025
- HCM 03-19-2025
- Dividend Yield
- PRCT N/A
- HCM N/A
- EPS Growth
- PRCT N/A
- HCM N/A
- EPS
- PRCT N/A
- HCM 0.04
- Revenue
- PRCT $249,121,000.00
- HCM $630,201,000.00
- Revenue This Year
- PRCT $47.40
- HCM $14.86
- Revenue Next Year
- PRCT $31.81
- HCM $19.54
- P/E Ratio
- PRCT N/A
- HCM $63.21
- Revenue Growth
- PRCT 59.36
- HCM N/A
- 52 Week Low
- PRCT $47.04
- HCM $11.51
- 52 Week High
- PRCT $103.81
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- PRCT 54.16
- HCM 50.07
- Support Level
- PRCT $55.18
- HCM $13.13
- Resistance Level
- PRCT $59.06
- HCM $13.66
- Average True Range (ATR)
- PRCT 2.64
- HCM 0.36
- MACD
- PRCT 0.16
- HCM 0.05
- Stochastic Oscillator
- PRCT 78.08
- HCM 81.25
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.